Find an expert

Organic functional materials development (design, synthesis & characterisation) for quantum based optoelectronics

Associate Professor Shih-Chun Lo (Lawrence)

Lawrence held a prestigious Swire Scholarship while carrying out his PhD study on semiconductor material development for organic solar cells and light emitting diodes (LEDs) at Oxford University, UK (1996-2000). His post-doctoral research at Oxford University focused on the design, synthesis and characterisation of fluorescent and phosphorescent dendrimers for highly efficient LEDs. Dendrimers have been recognised internationally as the third main class of LED materials, alongside small molecules and polymers, in which he played a key role. In December 2007, he joined the University of Queensland as a Lecturer in Chemistry of Materials. His research work has focused on the development of new functional semiconductor materials for quantum based optoelectronic applications (e.g. solar cells, LEDs, photodetectors, sensors, superconductors & organic lasers) as well as clean energy generation.

Biography

Jeffrey Mak (PhD) is an organic chemist at the Institute for Molecular Bioscience. His publications cover a range of disciplines such as biological and medicinal chemistry, total synthesis, and physical organic chemistry. Dr Mak was selected as a Rising Star of Chemistry by the Australian Journal of Chemistry (2022).

Jeffrey Mak was awarded the Harriett Marks Bursary and a UQ University Medal before undertaking doctorate studies in natural product total synthesis with Prof. Craig Williams. This culminated in the first total synthesis of two caged diterpenes, (−)-neovibsanin G and (−)-14-epi-neovibsanin G. Next, he joined Prof. David Fairlie's group at the Institute for Molecular Bioscience. He is currently active in the fields of chemical biology and drug development. He is recognised for his development of ligands that modulate mucosal associated invariant T (MAIT) cells, which are a newly characterised subset of immune cells important in antibacterial defence (Accounts of Chemical Research, 2021). In 2014, he was part of an Australian team that discovered the identity of the ligands that activate MAIT cells, as published in Nature, playing a key role in the chemical synthesis and characterisation of the unstable and structurally unprecedented ligands (Nature Communications, 2017). He was selected as a CAS SciFinder Future Leader by the Chemical Abstract Service (a division of the American Chemical Society, 2017). In 2018, Dr Mak was chief investigator on a UQ Early Career Researcher Grant for developing new drug leads that target MAIT cells. Other recent awards include RSC Twitter Poster Conference (Chemical Biology) 1st Prize (2018), and a CASS Travel Award (2018).

Dr Mak has lectured in the undergraduate course Advanced Organic Chemistry (CHEM3001, 2017-2023). He has also served as a member of the UQ Cultural Inclusion Council, and as an ACS Wikipedia Fellow to systematically improve the chemistry and scientific content on Wikipedia (2018).

Student projects

Projects in medicinal chemistry, synthesis, and chemical biology are available (depending on lab space) for enthusiastic organic chemistry students at all levels (PhD, Masters, Honours, Undergraduate). These include the design and synthesis of:

1. Stable analogues of immunostimulating bacterial ligands towards vaccines and anti-cancer immunotherapies
2. Chemical biology tools for exploring MAIT cell activation
3. Highly selective histone deacetylase (HDAC) inhibitors as new drug leads

Previous student publications:

1. Mak JYW* et al. (2024) Potent Immunomodulators Developed from an Unstable Bacterial Metabolite of Vitamin B2 Biosynthesis. Angewandte Chemie, e202400632.
2. Mak JYW et al. (2021) HDAC7 inhibition by phenacetyl and phenylbenzoyl hydroxamates. Journal of Medicinal Chemistry, 64 (4), 2186-2204.
3. Awad W, Ler GJM et al. (2020) The molecular basis underpinning the potency and specificity of MAIT cell antigens. Nature Immunology, 21 (4), 400-411.
4. Ler GJM, Xu W, Mak JYW, Liu L et al. (2019) Computer modelling and synthesis of deoxy and monohydroxy analogues of a ribitylaminouracil bacterial metabolite that potently activates human T cells. Chemistry – A European Journal, 25 (68), 15594-15608.

Professor Mobli is a structural biologist and a group leader at the University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN). He is well known internationally for his contributions to the basic theory of multidimensional nuclear magnetic resonance and its applications to resolving the molecular structure of peptides and proteins, as well as studying their physiochemical properties and function. Mehdi's contributions to the field has been recognised by being appointed an Executive Editor of the AMPERE society's journal "Magnetic Resonance", and to the advisory board of the international Biological Magnetic Resonance Data Bank (BMRB) as well as serving on the board of directors of the Australia and New Zealand Society for Magnetic Resonance (ANZMAG). He is a former ARC Future Fellow and recipient of the ASBMB MERCK medal, the Australia Peptide Society's Tregear Award, the ANZMAG Sir Paul Callaghan medal and the Lorne Proteins Young Investigator Award (now Robin Anders Award).

Prof. Mobli's research group focuses on characterising the structure and function of receptors involved in neuronal signalling, with a particular focus on developing new approaches for the discovery and characterisation of modulators of these receptors through innovations in bioinformatics, biochemistry and and biophysics. This work has led to publication of more than 100 research articles attracting over 6,000 citations.

Associate Professor Muttenthaler is a medicinal chemist working at the interface of chemistry and biology with a strong passion for translational research. His research focuses on bioactive peptides and exploring Nature's biodiversity to develop advanced molecular tools, diagnostics, and therapeutics. His background in drug discovery and development, as well as his interdisciplinary training in the fields of chemistry, molecular biology and pharmacology, assist him in characterising these often highly potent and selective compounds to study their interactions with human physiology for medical innovations in pain, cancer, gut disorders and neurological diseases.

Dr Ben Ross is a chemist with interests in medicinal chemistry, computer-aided drug design, virtual screening, synthetic chemistry, enzyme inhibitors, ion channel modulators, antivirals, amyloid diseases, neurodegenerative diseases, and cancer.

Follow Dr Ben Ross and his team on Twitter: @RossChemLab ||| Google Scholar: Benjamin P. Ross ||| ResearcherID: A-9573-2012 ||| ORCID: 0000-0002-1899-8484 ||| Scopus Author ID:7401608823 ||| Group Web Page: www.drbenross.com

Research Interests

The main focus of Dr Ben Ross's research is the application of computer-aided drug design and synthetic chemistry to create new drug candidates for cancer, viral infections, and neurodegenerative diseases such as Alzheimer’s disease. His team's novel molecules are evaluated using a variety of biochemical, biophysical, and cell-based screening assays, as well as animal models of disease, both within their lab and in partnership with local and international collaborators. Consideration of drug-likeness is an integral part of the design process, since good ADMET properties are crucial for their molecules to reach the clinic.

Biography

Ben Ross graduated with a First-Class Honours Degree in Chemistry (1999) and then moved to the UQ School of Pharmacy where he gained a Doctorate in the field of Medicinal Chemistry (2004). He worked in the School of Molecular and Microbial Sciences as a Postdoctoral Research Fellow with Dr Ross McGeary for two years (2004-2006) during which he completed the synthesis of a variety of biologically useful molecules. In June 2006 Ben was appointed to a Lectureship within the UQ School of Pharmacy. In the first half of 2012 he was a Guest Researcher in the Department of Biochemistry and Structural Biology, Lund University, Sweden. In 2013 Ben was promoted to Senior Lecturer at UQ. A general theme of his research is medicinal chemistry, specifically the application of synthetic chemistry and molecular modeling to discover novel molecules with application as drugs or tools for research. Ben's team has published extensively in journals having a moderate-to-high impact factor in their specialised area of research (e.g. Journal of Medicinal Chemistry, Nanoscale, Food Chemistry).

Selected Primary Research Articles

Bifunctional Succinylated ε-Polylysine Coated Mesoporous Silica Nanoparticles for pH-Responsive and Intracellular Drug Delivery Targeting the Colon. C.T.H. Nguyen, R.I. Webb, L.K. Lambert, E. Strounina, E.C. Lee, M.-O. Parat, M.A. McGuckin, A. Popat, P.J. Cabot, B.P. Ross*. ACS Applied Materials & Interfaces 2017, 9, 9470-9483. doi:10.1021/acsami.7b00411 (2016 JIF 7.5, Quartile 1)

Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening. S.N. Dighe, G.S. Deora, E. De la Mora, F. Nachon, S. Chan, M.-O. Parat, X. Brazzolotto*, B.P. Ross*. Journal of Medicinal Chemistry 2016, 59, 7683-7689. doi:10.1021/acs.jmedchem.6b00356 (Featured on the front cover of the journal: http://pubs.acs.org/toc/jmcmar/59/16) (2016 JIF 6.3, Quartile 1)

GAG mimetic functionalised solid and mesoporous silica nanoparticles as viral entry inhibitors of herpes simplex type 1 and type 2 viruses. E.C. Lee, N. Davis-Poynter*, C.T.H. Nguyen, A.A. Peters, G.R. Monteith, E. Strouina, A. Popat*, B.P. Ross*. Nanoscale 2016, 8, 16192-16196. doi:10.1039/C6NR03878F (2016 JIF 7.4, Quartile 1)

Metal chelation, radical scavenging and inhibition of Aβ42 fibrillation by food constituents in relation to Alzheimer’s disease. S. Chan, S. Kantham, V.M. Rao, M.K. Palanivelu, H.L. Pham, P.N. Shaw, R.P. McGeary, B.P. Ross*. Food Chemistry 2016, 199, 185-194. doi:10.1016/j.foodchem.2015.11.118 (2016 JIF 4.5, Quartile 1)

"Click" Assembly of Glycoclusters and Discovery of a Trehalose Analogue that Retards Aβ40 Aggregation and Inhibits Aβ40-induced Neurotoxicity. H. Rajaram, M.K. Palanivelu, T.V. Arumugam, V.M. Rao, P.N. Shaw, R.P. McGeary, B.P. Ross*. Bioorganic & Medicinal Chemistry Letters 2014, 24, 4523-4528. doi:10.1016/j.bmcl.2014.07.077 (2014 JIF 2.4, Quartile 3)

Enzyme-Responsive Controlled Release of Covalently Bound Prodrug from Functional Mesoporous Silica Nanospheres. A. Popat, B.P. Ross, J.Liu, S. Jambhrunkar, F. Kleitz*, S.Z. Qiao*. Angewandte Chemie International Edition 2012, 51, 12486-12489. doi:10.1002/anie.201206416 (2010 JIF 13.7, Quartile 1)

PhD vacancies - PhD opportunities

Australian and international students with backgrounds in chemistry, biochemistry, and pharmacy are encouraged to contact Dr Ben Ross to discuss possible Honours or PhD projects and scholarships.

Sources of funding include: UQ Scholarships; NHMRC Postgraduate Scholarships; Endeavour Scholarships and Fellowships; Malaysia Ministry of Higher Education (MOHE) Scholarships; Ministry of Education Saudi Arabia; and the China Scholarship Council (CSC), as well as many other funding schemes. Contact Dr Ben Ross via email to discuss the best strategy to obtain a scholarship.

Teaching and Service Activities

Dr Ben Ross is the Research Higher Degrees Coordinator for the School of Pharmacy, and an Academic Advisor for Year 2 of the BPharm(Hons) program. He also coordinates and teaches within the following undergraduate BPharm(Hons) courses:

PHRM2021 Dosage Form Design A1;

PHRM2022 Dosage Form Design A2;

PHRM2040 Drug Discovery A1;

PHRM2041 Drug Discovery A2 - Course Coordinator;

PHRM3021 Dosage Form Design B1.

Dr Viviene Santiago is a Postdoctoral Research Fellow in the Natural Toxins group within the Centre for Animal Science, Queensland Alliance for Agriculture and Food Innovation (QAAFI) and is based at the Health and Food Sciences Precinct (Coopers Plains). With a robust foundation in organic and analytical chemistry, her research primarily focuses on natural products chemistry from terrestrial, marine, and microbial sources.

Dr Santiago joined QAAFI as a Postdoctoral Research Fellow in 2023. Her current research involves developing a delivery system for bioactive compounds aimed at reducing enteric methane emissions in cattle and exploring atypical sugars in novel foods such as stingless bee honey. Over the years, she has cultivated a keen interest in utilising liquid chromatography-mass spectrometry (LC-MS) and molecular networking techniques to investigate chemical diversity from different sources such as natural toxins in certain plants and atypical sugars in stingless bee honey.

Dr Santiago earned her Ph.D. from The University of Queensland, where her dissertation focused on applying advanced molecular networking techniques, such as the Global Natural Products Social Molecular Networking (GNPS), to explore the chemical diversity of Australian microbes. Her academic journey also includes a Master’s and a Bachelor’s degree in Chemistry from the University of the Philippines – Diliman. These academic experiences have equipped her with a comprehensive understanding of natural products chemistry, enabling her to make significant contributions to both academia and industry.

Mariusz Skwarczynski completed his Ph.D. in Chemistry in 1999 at Wroclaw University of Technology (Poland). His postdoctoral training began at Tokushima Bunri University (Japan) under the direction of late Professor M. Nishizawa, where he studied the biomimetic total synthesis of anticancer agent paclitaxel. He then joined the laboratory of Professor Yoshiaki Kiso at Kyoto Pharmaceutical University (Japan) to study prodrugs of paclitaxel. In 2004 he was awarded with Japanese fellowship (Japan Society for the Promotion of Science postdoctoral fellowship) and research grant to conduct further research on paclitaxel. He developed novel classes of paclitaxel prodrugs: isotaxoids and phototaxels. He also co-developed an epimerization-free method for the synthesis of novel building blocks (isodipeptides) for solid phase peptide synthesis and these units have been commercialized by Merck-Novabiochem.

In 2008 he joined Professor Istvan Toth group at University of Queensland (Australia) to work on vaccine delivery strategies. Since then, he research is mainly focused on nanotechnology-based peptide vaccine delivery approaches. In 2010 he was awarded with University of Queensland Strategic Fund Research Fellowship. In Australia, he is involved in a wide range of collaborative research projects, both nationally and internationally, to develop vaccines against GAS, HIV, hookworm infections, malaria and cancer, along with antibiotics against multidrug resistant bacteria.

I began my scientific career with a Bachelor of Science in Biochemistry and Chemistry, followed by a Bachelor of Science with First Class Honours in Chemistry from Massey University, New Zealand. My honours project focused on developing hydrogels for controlled peptide release in the gut. I then pursued a PhD at Massey University, working on synthetic anti-cancer drugs based on cyclodextrins.

After completing my PhD, I worked as a Research Officer at the New Zealand Veterinary Pathology Epicentre, refining my diagnostic research skills. I continued my career as a Postdoctoral Fellow at Kansas State University, contributing to the detection and surveillance of zoonotic diseases in the swine industry.

Currently, at the University of Queensland, I integrate my expertise in synthetic peptides with vaccine development. My research bridges medical and agricultural biotechnology, focusing on innovative adjuvants and vaccines that span medicinal chemistry, nanotechnology, and immunology, aiming to enhance both health outcomes and agricultural practices.

Professor István Tóth is Chair in Biological Chemistry at The University of Queensland (UQ), Brisbane, Australia, and Affiliated Professorial Research Fellow at the Institute of Molecular Biosciences, UQ. He graduated with a degree in Chemical Engineering from the Technical University, Budapest, Hungary and was awarded his PhD for his Alkaloid Chemistry research. Professor Tóth undertook a postdoctoral fellowship at Carleton University, Ottawa Canada before returning to Hungary to work as a Research Associate, then Scientific Group Leader at the Central Research Institute for Chemistry, Hungarian Academy of Science. He joined the School of Pharmacy at the University of London in 1987 as a Senior Lecturer and Royal Society sponsored Senior Research Fellow. He became a Reader in Medicinal Organic Chemistry in 1994 and was awarded a Doctor of Science degree (DSc 1994) for his work in Drug Delivery (Hungarian Academy of Sciences), before relocating to the University of Queensland in 1998 where he has built a productive research group. Professor Tóth was a visiting professor at the School of Pharmacy, University of London (1994-2004) and at the Department of Bioengineering and Therapeutic Science, University of California, San Francisco (2011-2013). Professor Tóth’s major research interests are: drug delivery, immunoadjuvants, carbohydrates, lipids, peptides, nucleosides, and nucleotides. This research has attracted over $85 million in competitive grants, research contracts and investment funds in the past 10 years. Professor Tóth has over 500 peer-reviewed publications, 45 patents, and an excellent track record in research commercialisation. He is a one of key founders of Alchemia, Implicit Bioscience Pty Ltd, Neurotide Pty Ltd and TetraQ (the commercial arm of Centre of Integrated Preclinical Drug Development). Professor Tóth is an elected RACI Fellow and Fellow of the Queensland Academy of Arts and Sciences. and Feklloiw of the Hungarian Academy of Sciences (since 2016) In 2009 he was awarded the Adrian Albert award for sustained and outstanding research in medicinal biochemistry, and a Business/Higher Education Round Table (BHERT) Award for Outstanding Achievement in International Collaborative Research and Development he obtained the Doctor Honoris Causa degree at Semmelweis university budapest Hungary (2019). Professor Tóth was appointed as a member of the ARC College of Experts (2008-2010). He was the founding (2007) then the elected (2008-2009) President of the Australian Chapter of Controlled Release Society.

Associate Professor Ryan Turner is the Director of the Reef Catchments Science Partnership at the University of Queensland (a partnership with the Department of the Environment, Tourism, Science and Innovation). Ryan was previously the Department's Principal Scientist for Water Quality and Investigations and held an Adjunct Associate Professor role at Queensland University of Technology in the Managing for Resilient Landscapes, Institute for Future Environments. For 14 years, Ryan managed multimillion-dollar water quality monitoring programs assessing the impacts of sediments, nutrients, and pesticides in numerous catchments along the Queensland coast discharging to the Great Barrier Reef and Moreton Bay. Ryan has been on several steering committees and technical advisory panels, such as the Great Barrier Reef Foundations Technical Advisory Panel. He has published extensively (>80 papers and reports) and led several Queensland Government – Academic collaborative research projects. Ryan previously supervised analytical chemistry and microbiology laboratories in the private and public sectors. Ryan has developed numerous methodologies and standard operating procedures for analytical and monitoring techniques (water quality, sediments and soils). Ryan’s passion for the future of water security is what keeps him striving forward.

Educated at the University of Copenhagen, Denmark, and the Australian National University, Canberra. Career at the Université de Lausanne, Switzerland, and the Universität Marburg, Germany. Professor and Chair of Organic Chemistry and Head of the Organic Chemistry Section, The University of Queensland from 1985. Emeritus professor from 2008. Chair of the National Committee for Chemistry of the Australian Academy of Science 2009-2014. Editor-in-Chief, Australian Journal of Chemistry 2008-15. Editor, Journal of Analytical and Applied Pyrolysis (Elsevier, IF 3.65) 2016-. Visiting Professor Université de Pau, France, 2011-19; Visiting Professor University of Kuwait 2014-18; Visiting Professor / Special Appointed Professor Hiroshima University 2014-18. Fellow of the Australian Academy of Science. Centenary Medal of the Australian Commonwealth 2003 for research in organic and physical chemistry. David Craig Medal of the Academy of Science 2014 for research in chemistry. JSPS Fellowship (Japan) 2014. Honorary doctorate, University of Pau, France, 2014. A.J. Birch Medal of the Royal Australian Chemical Institute (RACI) for ecellence in research in organic chemistry, 2014. Leighton Medal of the RACI 2018.

Research on Unusual Molecules and Reactive Intermediates: Synthesis and Reaction Mechanism. Heterocyclic chemistry. Pyrolysis reactions. Photochemistry

Research in the Wentrup group is concerned with the discovery of novel types of molecules with new and unusual bonding patterns. Such molecules are mostly highly reactive, and special methods are required both for their generation and for their detection. The group has developed these methods over many years and acquired world-class equipment for these purposes, including flash vacuum thermolysis apparatus, cryostats for matrix isolation of reaction products at cryogenic temperatures (down to 7 K), matrix and solution photochemistry equipment, infrared, UV and mass spectrometers, as well as modern computational facilities.

This research has resulted in the synthesis and characterization of many novel compounds, including extended cumulenes of the types RN=C=C=C=X, which themselves are used in the synthesis of many novel types of molecules, some of them of potential pharmaceutical interest (quinolone antibiotics; diazepines).

The research group has a world reputation in the field of carbene and nitrene chemistry, involving reactive intermediates with sextet carbon or nitrogen. These species are also very useful in synthesis, for example in the preparation of diazepines and diazepinones, a family of pharmaceutically interesting compounds. Numerous mechanistic studies and synthetic applications of ketenes have been carried out in our group.

Active collaborations are ongoing with scientists in Australia (UQ and CSIRO), China (Suzhou), France (Pau), Germany (Oldenburg), Japan (Hiroshima), Spain (Donostia - San Sebastian), and Portugal (Coimbra).

Craig M. Williams was born in Adelaide, Australia. He received his B.Sc. (Hons) degree in chemistry in 1994 from Flinders University. In 1997, he was awarded his Ph.D. in organic chemistry from the same institution under the supervision of Professor Rolf H. Prager. He undertook post-doctoral studies as an Alexander von Humboldt Fellow working with Professor Armin de Meijere at the Georg-August-Universität, Göttingen, Germany, from 1997 to 1999. In early 1999, he accepted a second post-doctoral fellowship at the Australian National University with Professor Lewis N. Mander.

Professor Williams has held an academic position at the University of Queensland since 2000, and during this time has won a number of awards including a Thieme Chemistry Journals Award in 2007, an Australian Research Council Future Fellowship award in 2011, and the Award for Outstanding Contribution to Research (SCMB, UQ, 2019). The Williams research group explores numerous interests within the discipline of organic chemistry (e.g. medicinal chemistry, fundamental molecules, natural productisolation, microelectronics, drug and agrichemical development, impact sensitive molecules) enabled by organic synthesis refined through the construction of biologically active complex natural products (diterpenes, polyketides, alkaloids), and designs synthetic methodology to assist in this endeavour (synthetic transformations and reagents). Professor Williams especially enjoys teaching whole molecule retrosynthesis to undergraduate and post-graduate students.

Dr. Norhasnida Zawawi has been an Honorary Senior Fellow at the Queensland Alliance for Agriculture and Food Innovation (QAAFI) since 2019. She has joined the Australian Native Bee Association (ANBA) subcommittee for the development of native bee honey standard application to Food Standards and Australia and New Zealand (FSANZ) since 2020. Currently based in Malaysia, she is a senior lecturer at the Department of Food Science, Faculty of Food Science and Technology (FSTM), Universiti Putra Malaysia (UPM) and a food and nutritional scientist affiliated with two laboratories, the Laboratory of Functional Carbohydrate and Protein at FSTM and Laboratory of Halal Science at the Halal Products Research Institute, both in UPM. Her administration and research responsibilities include being a member of the Working Group for Kelulut Honey (native bee honey) Standard under the Department of Standards Malaysia, Ministry of International Trade and Industry (MITI), Malaysia, and Vice President of the Task Group for Stingless Bee Honey Standard elected by Apimondia Asia. Recently, she has been appointed as an Editorial Board Member of the Pertanika Journal of Tropical Agricultural Science, one of UPM's publications and have had experiences as reviewer of scientific manuscripts in her field of research for many high-impact factor journals such as Food Research International, Current Research in Food Science, Food Bioscience and Journal of Apicultural Research. Together with QAAFI research team, she has made the discovery of a rare sugar (trehalulose) as the primary sugar available in the native bee honey during her 9 months research attachment in 2018. As the principal investigator for 7 research projects, she was awarded grants from UPM and government ministries amounting to RM906,340.00. Currently, thirty-seven of her research publications are Scopus-indexed with a total of 624 citations, earning her the H-index of 17.

Dr Zyta Ziora received PhD (Wroclaw University of Science & Technology, Poland) in chemistry and has wide range of experience in development of antimalarial therapeutics (the University of Montpellier, France), antibacterial agents, enzyme inhibitors and drug candidates against Alzheimer disease (Kyoto Pharmaceutical University, Japan). Her research time is currently dedicated mainly to projects devoted to the modification of existing antibiotics, and complexing them with additional antimicrobial agents, like metal ions, to produce more potent alternatives and by this to overcome the drug resistance of superbugs. She is also working on alternative to antibiotics nature-derived compounds with antimicrobial and anticancer potency, such poliphenolic derivatives to control tyrosinase function.